Should I buy or sell CytomX Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTMX shares. View CTMX analyst ratings or view top-rated stocks .

What is CytomX Therapeutics' stock price target for 2024?

2 analysts have issued 1-year target prices for CytomX Therapeutics' shares. Their CTMX share price targets range from $3.00 to $3.19. On average, they anticipate the company's share price to reach $3.10 in the next year. This suggests a possible upside of 84.8% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts .

How have CTMX shares performed in 2024?

CytomX Therapeutics' stock was trading at $1.55 at the beginning of the year. Since then, CTMX shares have increased by 8.1% and is now trading at $1.6750. View the best growth stocks for 2024 here .

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 3,320,000 shares, a decline of 5.9% from the March 15th total of 3,530,000 shares. Based on an average trading volume of 864,800 shares, the days-to-cover ratio is presently 3.8 days. View CytomX Therapeutics' Short Interest .

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CTMX earnings forecast .

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Monday, March, 11th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.01. The biotechnology company had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million.

What ETF holds CytomX Therapeutics' stock?

Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com . Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD) , Exelixis (EXEL) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) , Corbus Pharmaceuticals (CRBP) , Pfizer (PFE) , SCYNEXIS (SCYX) , Bausch Health Companies (BHC) , Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX) .

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Park Capital LLC (0.35%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy . View institutional ownership trends .

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CTMX Stock Alerts

$1.67

-0.06 (-3.47%)

(As of 04:00 PM ET)

Compare

Today's Range: $1.64
▼
$1.75
50-Day Range: $1.41
▼
$2.74
52-Week Range: $1.04
▼
$2.86

Volume: 505,550 shs
Average Volume: 855,119 shs
Market Capitalization: $113.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.10

Get CytomX Therapeutics alerts:

CytomX Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 84.8% Upside
$3.10 Price Target
Short Interest: Healthy
4.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.74
Upright™ Environmental Score
News Sentiment: 0.96
Based on 4 Articles This Week
Insider Trading: Selling Shares
$73,200 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.21) to ($0.29) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.32 out of 5 stars

Medical Sector

97th out of 918 stocks

Pharmaceutical Preparations Industry

29th out of 417 stocks

3.3

Analyst's Opinion

Consensus Rating
CytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
CytomX Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
4.90% of the outstanding shares of CytomX Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
CytomX Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CytomX Therapeutics has recently decreased by 5.95%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
CytomX Therapeutics does not currently pay a dividend.
Dividend Growth
CytomX Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for CytomX Therapeutics is -0.74.

2.8

News and Social Media Coverage

News Sentiment
CytomX Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 1 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,200.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of CytomX Therapeutics is held by insiders.
Percentage Held by Institutions
67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.21) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CytomX Therapeutics is -83.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CytomX Therapeutics is -83.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About CytomX Therapeutics Stock (NASDAQ:CTMX)

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CTMX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTMX Stock News Headlines

March 22, 2024 | insidertrades.com

CytomX Therapeutics, Inc. (NASDAQ:CTMX) General Counsel Lloyd A. Rowland Sells 5,268 Shares

April 18, 2024 | americanbankingnews.com

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 5.9% in March

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | finance.yahoo.com

CytomX Therapeutics, Inc. (CTMX)

April 8, 2024 | globenewswire.com

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

April 3, 2024 | globenewswire.com

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

March 23, 2024 | investing.com

CytomX Therapeutics executive sells over $26k in company stock

March 23, 2024 | investing.com

CytomX Therapeutics executive sells shares worth over $6,000

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | globenewswire.com

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

March 18, 2024 | globenewswire.com

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

March 13, 2024 | finance.yahoo.com

CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 12, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN) and CytomX Therapeutics (CTMX)

March 12, 2024 | markets.businessinsider.com

J.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)

March 12, 2024 | finance.yahoo.com

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript

March 12, 2024 | investorplace.com

Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?

March 12, 2024 | benzinga.com

Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

March 11, 2024 | marketwatch.com

Stocks to Watch: Oracle, Mission Produce, CytomX Therapeutics

March 11, 2024 | marketwatch.com

CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate

March 11, 2024 | benzinga.com

Recap: CytomX Therapeutics Q4 Earnings

March 11, 2024 | globenewswire.com

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

March 8, 2024 | benzinga.com

CytomX Therapeutics's Earnings Outlook

March 4, 2024 | globenewswire.com

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

February 28, 2024 | ca.finance.yahoo.com

BMY Oct 2024 45.000 put

February 27, 2024 | ca.finance.yahoo.com

BMY Apr 2024 52.000 put

February 27, 2024 | ca.finance.yahoo.com

BMY Aug 2024 60.000 call

February 27, 2024 | globenewswire.com

CytomX Therapeutics to Present at Upcoming March Investor Conferences

See More Headlines

Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CTMX
CUSIP: N/A
CIK: 1501989
Web: www.cytomx.com
Phone: (605) 515-3185
Fax: 650-351-0353
Employees: 120
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.10
High Stock Price Target: $3.19
Low Stock Price Target: $3.00
Potential Upside/Downside: +79.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-570,000.00
Net Margins: -0.56%
Pretax Margin: 3.28%
Return on Equity: N/A
Return on Assets: -0.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.17
Quick Ratio: 1.17

Sales & Book Value

Annual Sales: $101.21 million
Price / Sales: 1.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.71) per share
Price / Book: -2.42

Miscellaneous

Outstanding Shares: 67,730,000
Free Float: 62,991,000
Market Cap: $116.50 million
Optionable: Optionable
Beta: 1.00

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Sean A. McCarthy DPHIL (Age 57)
Chairman & CEO
Comp: $1.03M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTMX Stock Analysis - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTMX shares.
View CTMX analyst ratings or view top-rated stocks.
What is CytomX Therapeutics' stock price target for 2024?: 2 analysts have issued 1-year target prices for CytomX Therapeutics' shares. Their CTMX share price targets range from $3.00 to $3.19. On average, they anticipate the company's share price to reach $3.10 in the next year. This suggests a possible upside of 84.8% from the stock's current price.
View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts.
How have CTMX shares performed in 2024?: CytomX Therapeutics' stock was trading at $1.55 at the beginning of the year. Since then, CTMX shares have increased by 8.1% and is now trading at $1.6750.
View the best growth stocks for 2024 here.
Are investors shorting CytomX Therapeutics?: CytomX Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 3,320,000 shares, a decline of 5.9% from the March 15th total of 3,530,000 shares. Based on an average trading volume of 864,800 shares, the days-to-cover ratio is presently 3.8 days.
View CytomX Therapeutics' Short Interest.
When is CytomX Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CTMX earnings forecast.
How were CytomX Therapeutics' earnings last quarter?: CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Monday, March, 11th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.01. The biotechnology company had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million.

What ETF holds CytomX Therapeutics' stock?: Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.
What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?: 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.
What other stocks do shareholders of CytomX Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).
Who are CytomX Therapeutics' major shareholders?: CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Park Capital LLC (0.35%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy.
View institutional ownership trends.
How do I buy shares of CytomX Therapeutics?: Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTMX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial